Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

A powerful new lab-made opioid is moving through the illegal US drug supply, and federal officials warn it could keep spreading. The drug, called cychlorphine, may be up to 10 times stronger than ...

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Highest ASCVD risk at follow-up seen for those who remained in or transitioned into low exposure categories over one year ...

The new biosimilar offers an additional treatment option for patients with multiple myeloma, bone metastases, and giant cell tumors of the bone.

FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.

Betzaida Tejada-Vera, from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from all death certificates filed in the 50 states and the District of Columbia ...

Modest decline seen in 30-day case fatality rates over time among young adults, driven by intracerebral hemorrhage, subarachnoid hemorrhage.

Associations included higher prevalence of focal to bilateral tonic-clonic seizures in drug-resistant epilepsy ...